Trial Profile
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone) in Children With Pearson Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vatiquinone (Primary)
- Indications Mitochondrial disorders
- Focus Therapeutic Use
- Sponsors BioElectron Technology
- 23 Nov 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 21 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Aug 2014 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.